A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C.

Hauser, P; Khosla, J; Aurora, H; Laurin, J; Kling, M A; Hill, J; Gulati, M; Thornton, A J; Schultz, R L; Valentine, A D; Meyers, C A; Howell, C D

Hauser, P; Khosla, J; Aurora, H; Laurin, J; Kling, M A; Hill, J; Gulati, M; Thornton, A J; Schultz, R L; Valentine, A D; Meyers, C A; Howell, C D.

Affiliation

Hauser P; Portland VA Medical Center, Behavioral Health and Neurosciences Division, NW Hepatitis C Field Based Resource Center/Oregon Health & Sciences University, Portland, OR 97201, USA. Peter.Hauser2@med.va.gov

Mol Psychiatry ; 7(9): 942-7, 2002.

Article in En | MEDLINE | ID: mdl-12399946

Subject(s)

Antidepressive Agents, Second-Generation/administration & dosage; Antiviral Agents/adverse effects; Citalopram/administration & dosage; Depressive Disorder, Major/drug therapy; Hepatitis C/drug therapy; Interferons/adverse effects; Adult; Depressive Disorder, Major/chemically induced; Female; Hepatitis C/psychology; Humans; Incidence; Male; Middle Aged; Prospective Studies; Treatment Outcome

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Antiviral Agents / Citalopram / Interferons / Hepatitis C / Antidepressive Agents, Second-Generation / Depressive Disorder, Major Type of study: Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Mol Psychiatry Journal subject: BIOLOGIA MOLECULAR / PSIQUIATRIA Year: 2002 Document type: Article Affiliation country: United States

Search on Google

Add to My VHL

XML

PubMed Links